Understanding Lebrikizumab: A New Hope for Eczema│ Pharmacology: Mechanism of Action

In September 2004, the U.S. Food and Drug Administration approved lebrikizumab (Ebglyss; Eli Lilly) for patients 12 and older with moderate to severe atopic dermatitis. This new biologic treatment offers relief to those whose skin condition isn’t effectively managed with topical medications. The video explains how lebrikizumab works and highlights the clinical trial results that supported its FDA approval. Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References: 1. https://nationaleczema.org/eczema/typ... 2. Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019 Jul;28(7):756-768. doi: 10.1111/exd.13911. Epub 2019 Apr 15. PMID: 30825336; PMCID: PMC6850480. 3. https://www.hcplive.com/view/fda-appr... 4. https://investor.lilly.com/news-relea... 5. Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. PMID: 36920778. 6. Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, Blauvelt A; ADhere Investigators. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. 2023 Feb 1;159(2):182-191. doi: 10.1001/jamadermatol.2022.5534. Erratum in: JAMA Dermatol. 2023 Sep 1;159(9):1014. doi: 10.1001/jamadermatol.2023.2199. PMID: 36630140; PMCID: PMC9857439. #atopicdermatitis #skincare #allergy #eczema #lebrikizumab #ebglyss #biologictreatment #immunotherapy